Press Releases March 30, 2026 08:00 PM

BOSS Zhipin Continues Share Repurchases, with Total Repurchases Amounting to Over RMB576 Million in 2026

KANZHUN LIMITED Advances Share Repurchase Program, Spending Over RMB576 Million in 2026

By Sofia Navarro BZ
BOSS Zhipin Continues Share Repurchases, with Total Repurchases Amounting to Over RMB576 Million in 2026
BZ

KANZHUN LIMITED (BOSS Zhipin) announced the continuation of its share repurchase program, having spent approximately RMB34.5 million to buy back 744,334 shares on March 30, 2026. Total repurchases for the year so far exceed RMB576 million, demonstrating the company's focus on enhancing shareholder value.

Key Points

  • KANZHUN LIMITED has repurchased over RMB576 million worth of shares year-to-date in 2026.
  • The company repurchased 744,334 ordinary shares on March 30 using RMB34.5 million.
  • The ongoing share buyback program highlights management's commitment to returning value to shareholders.
  • The company's actions impact the technology and internet sectors, particularly online recruitment and HR services markets.

BEIJING, March 31, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing around RMB34.5 million to repurchase 744,334 ordinary shares on March 30. Year-to-date in 2026, the Company has deployed over RMB576 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.


Risks

  • Continued allocation of funds to share repurchases may limit capital available for business expansion or R&D.
  • Market volatility could affect the timing and scale of repurchases.
  • Changes in regulatory environment affecting stock buybacks could impact the program.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026